(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral poly ...

Singapore sovereign wealth fund Temasek plans to deploy another $10 billion in India over the next 2 to 3 years, focusing on ...

Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.

The Million Dollar Sellers group convened last week in New York City during and around Amazon’s own Seller Growth Summit ...

"If you are at all concerned... visit your local doctor or GP." ...

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued development in sickle cell disease (SCD), leading the co ...

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms. The method, published June 30 in Leukemia, ...

Cellares secures new funding, partnerships and FDA recognition as it prepares for commercial-scale cell therapy manufacturing ...

Capital markets regulator Securities and Exchange Board of India (SEBI) on Friday cautioned listed companies and regulated ...

Operation Brock, the traffic management scheme that diverts lorries heading to the Dover and Folkestone ports to the M20 ...

CEBPA mutations in MDS are uncommon but associated with shorter survival and an increased risk of AML transformation.